These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
34. Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study. Kjeldsen SE, Devereux RB, Hille DA, Lyle PA, Dahlöf B, Julius S, Edelman JM, Snapinn SM, de Faire U, Fyhrquist F, Ibsen H, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Blood Press; 2009 Jun; 18(6):348-61. PubMed ID: 20001655 [Abstract] [Full Text] [Related]
38. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]. Ibsen H, Lindholm LH, Pedersen OL, Dahlöf B, Kjeldsen S. Ugeskr Laeger; 2003 Jan 27; 165(5):459-62. PubMed ID: 12599844 [Abstract] [Full Text] [Related]
39. Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study. Ariansen I, Reims HM, Gjesdal K, Olsen MH, Ibsen H, Devereux RB, Okin PM, Kjeldsen SE, Dahlöf B, Wachtell K. Blood Press; 2012 Feb 27; 21(1):6-11. PubMed ID: 22070095 [Abstract] [Full Text] [Related]